Seamus Mulligan, Director at Jazz Pharmaceuticals plc (JAZZ), sold 54,536 shares at $151.51 ($8.2M) on 2016-05-24, disclosed to the SEC on 2016-05-26.
Open-market sale of $8.2M JAZZ by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $148.65 | 1,400 | $208K | 2.5% |
| 2 | $149.64 | 11,888 | $1.8M | 21.7% |
| 3 | $149.64 | 11,888 | $1.8M | 21.7% |
| 4 | $150.72 | 9,954 | $1.5M | 18.3% |
| 5 | $150.72 | 9,954 | $1.5M | 18.3% |
| 6 | $151.51 | 4,726 |
| $716K |
| 8.7% |
| 7 | $151.51 | 4,726 | $716K | 8.7% |
| Total | $150.33 avg | 54,536 | $8.2M | 100% |
| Filing → |
| JAZZ | BUY | 2018-11-19 | $14.2M | — | Filing → |
| JAZZ | SELL | 2016-08-26 | $6.0M | — | Filing → |
| JAZZ | SELL | 2016-02-24 | $6.9M | — | Filing → |